TITLE

The efficiency of Bonviva (Ibadronate) in women with pre-post menopause

AUTHOR(S)
Duraj, Valbona; Backa, Teuta; Rapushi, Edvin; Zoto, Artur; Roshi, Enver
PUB. DATE
October 2010
SOURCE
Medicinski Arhiv;2010, Vol. 64 Issue 4, p225
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Aim: our aim was to see the efficiency of Bonviva(Ibadronates) among in osteoporoses among women. Objectives: We chose this medicament which has the most acceptable price by all the GDP women's family and also this medicament which is at the new line of biphosphonate (Ibadronates),and has the most commodity of taken ones per morithly. For our proposal we include in our study all women age45 -60 years old (average 52.6±41), which have a physiologic menopause. All case was selected from ambulatory service without other diseases such are neoplasic which affect the bone, renal (creatinine clirens < 40ml/min),gastrointestinal, respiratory and high blood pressure were or have allergy from Bonviva excluded or from our study. The final number of subject s was 89 women. The women at the moment of selection have or no osteoporotic fracture. We measure also the high, age, weigh, BMI but except age other were not analyzed form us. The measure of body mass density (BMD) is the gold standard for to establish the diagnosis of osteoporosis. All subjects we measure the index of T-score (which represent the BMD),at the lumbar part of spine, which show the efficiency of Bonviva. T-Score was measure before treatment, after six months and after one year. The T-score was measure by DE XA (luriate one). Results. In order to measure the efficiency of Bonvines all cases the T-Score were analyzed from SPSS version 15 with ANOVA. The results of KNOVA show statistical significance (p<0.0001) between BMD before treatment (-3.12±0.49), BMD six months after treatment (-2.9±0.5) and after BMD one year(-2.7±0.5). The significance was also high (P<0.0001) when we compare also BMD six month and after one year. Conclusions Our results show the efficiency of Bonviva among women with pre, during and post menopause in osteoporoses. Ibadronate (Bonviva) increase the BMD in women with early menopauses, as results we prevent osteoporosis. Bonviva increases the BMD in women with established osteoporoses, as results we reduce the vertebral risk fracture.
ACCESSION #
55785872

 

Related Articles

  • Densitometry identifies women in whom treatment will reduce fracture risk. Cronholm, Peter F.; Barr, Wendy // Journal of Family Practice;Feb2003, Vol. 52 Issue 2, p114 

    The article examines whether osteoporosis screening decreases fracture risk in postmenopausal women. The study is a review of information that contained data about postmenopausal women and osteoporosis including searches of MEDLINE, HealthSTAR and Cochrane databases. The authors reviewed...

  • High weight or body mass index increase the risk of vertebral fractures in postmenopausal osteoporotic women. Matteo Pirro; Gianluigi Fabbriciani; Christian Leli; Laura Callarelli; Maria Manfredelli; Claudio Fioroni; Massimo Mannarino; Anna Scarponi; Elmo Mannarino // Journal of Bone & Mineral Metabolism;Jan2010, Vol. 28 Issue 1, p88 

    Abstract  In the general population, low body weight and body mass index (BMI) are significant risk factors for any fracture, but the specific association between body weight, BMI, and prevalence of vertebral fractures in osteoporotic women is not fully recognized. Hence, the...

  • Eldecalcitol improves chair-rising time in postmenopausal osteoporotic women treated with bisphosphonates. Jun Iwamoto; Yoshihiro Sato // Therapeutics & Clinical Risk Management;2014, Vol. 10, p51 

    An open-label randomized controlled trial was conducted to clarify the effect of eldecalcitol (ED) on body balance and muscle power in postmenopausal osteoporotic women treated with bisphosphonates. A total of 106 postmenopausal women with osteoporosis (mean age 70.8 years) were randomly divided...

  • Postmenopozal Kadınlarda Vücut Kitle Ä°ndeksinin Patellofemoral ve Tibiofemoral Eklem Osteoartriti Ãœzerine Olan Etkisi. Yanık, Burcu; Atalar, Hakan; Köktener, Aslı // Romatizma/Rheumatism;dic2007, Vol. 22 Issue 4, p123 

    Objective: Osteoarthritis is an important health problem with a multifactorial etiology. In this study, the effect of body mass index on patellofemoral and tibiofemoral osteoarthritis was investigated in 71 postmenopausal women. Patients and Methods: Ages of the patients were recorded. The body...

  • Atypical fractures not typical enough for definitive conclusions.  // Reactions Weekly;4/17/2010, Issue 1297, p3 

    The article discusses research which revealed a lack of association between bisphosphonate use and risk of atypical femoral fractures in elderly women receiving treatment for postmenopausal osteoporosis.

  • Independent Nurse: Clinical Solutions - Perimenopause.  // GP: General Practitioner;6/25/2010, p31 

    The article presents information on perimenopause. Perimenopause refers to the time between onset of menopausal symptoms until 12 months after the last menstruation. It is stated that the risk of cardiovascular disease (CVD) and osteoporosis, should be assessed, along with checking body mass...

  • Low Bone Mineral Density among Women : A Threatening Sign of Geriatric Osteoporosis. Baby, D.; Bharathi, R. // Indian Journal of Gerontology;2011, Vol. 25 Issue 1, p16 

    The article discusses a study on the tests done for bone mineral density (BMD) on 120 out patient women aged 35 to 70 years from Tirupati, India, at a local orthopedic hospital, in an attempt to predict current and future risk of geriatric osteoporosis. Results showed that 51.7% of the women...

  • Online tool to cut bone scan delays.  // Independent Nurse;10/20/2008, p8 

    The article presents information on FRAX, an online tool to evaluate fracture risk in patients with osteoporosis. The FRAX tool is designed to assess 10-year fracture risk in men who are more than 50 years old, and in women after the menopause. The test takes into account risk factors including...

  • The Association between Body Mass Index and Osteoporosis in Patients Referred for a Bone Mineral Density Examination. Asomaning, Kofi; Bertone-Johnson, Elizabeth R.; Nasca, Philip C.; Hooven, Frederick; Pekow, Penelope S. // Journal of Women's Health (15409996);Nov2006, Vol. 15 Issue 9, p1028 

    Purpose: Osteoporosis affects 4–6 million (13%–18%) postmenopausal white women in the United States. Most studies to date on risk factors for osteoporosis have considered body mass index (BMI) only as a possible confounder. In this study, we assess the direct relationship between...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics